MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Companyâs tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
äŒæ¥ã³ãŒãMDXH
äŒç€ŸåMDxHealth SA
äžå Žæ¥Jun 26, 2006
æé«çµå¶è²¬ä»»è
ãCEOãMr. Michael K. McGarrity
åŸæ¥å¡æ°312
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Jun 26
æ¬ç€Ÿæåšå°CAP Business Center
éœåžHERSTAL
蚌åžååŒæNASDAQ Capital Market Consolidated
åœBelgium
éµäŸ¿çªå·4040
é»è©±çªå·3243642070
ãŠã§ããµã€ãhttps://mdxhealth.com/
äŒæ¥ã³ãŒãMDXH
äžå Žæ¥Jun 26, 2006
æé«çµå¶è²¬ä»»è
ãCEOãMr. Michael K. McGarrity
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã